Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Profiling of ovarian tumour and benign lesions

ABSTRACT: Investigation of malignancy-associated expression of gene sets based on ovarian tumour histone modification status.

ORGANISM(S): Homo sapiens

PROVIDER: GSE41498 | GEO | 2012/10/12

SECONDARY ACCESSION(S): PRJNA177227

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Profiling of ovarian tumour and benign lesions

Project description:Investigation of malignancy-associated expression of gene sets based on ovarian tumour histone modification status. A single serous epithelial ovarian tumour (which was assayed using ChIP-seq to determine histone modification profiles; SRA059358) was profiled using the HGU133 plus 2 GeneChip, along with 8 benign ovarian lesions (1 serous cyst, 3 serous cystadenomas and 4 serous cystadenofibromas) for comparison. Expression levels of genes marked in the tumour with particular histone modifications were compared between the tumour and the benign samples.

2012-10-12 | E-GEOD-41498 | biostudies-arrayexpress

Transcription profiling of human ovarian tumour samples

Project description:This SuperSeries is composed of the following subset Series:; GSE9890: Expression profile of 5 ovarian tumour samples (two different cell types from each sample profiles); GSE9891: Expression profile of 285 ovarian tumour samples Experiment Overall Design: Refer to individual Series

2008-04-06 | E-GEOD-9899 | biostudies-arrayexpress

Transcription profiling of 285 human ovarian tumour samples

Project description:We used microarrays to profile the expression levels of 285 ovarian samples in order to identify molecular subtypes of the tumour Experiment Overall Design: Randomly selected samples from the AOCS ( Australian Ovarian Cancer Study) was expression profiled on the affymetrix U133_plus2 platform to identify novel subtypes of ovarian tumour

2008-04-06 | E-GEOD-9891 | biostudies-arrayexpress

Expression profile of 285 ovarian tumour samples

Project description:We used microarrays to profile the expression levels of 285 ovarian samples in order to identify molecular subtypes of the tumour Keywords: disease state analysis

2008-03-01 | GSE9891 | GEO

Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high grade serous ovarian cancer that distinguish malignant, tumour sustaining and chemo-resistant ovarian tumour cells.

Project description:This SuperSeries is composed of the following subset Series: GSE41498: Profiling of ovarian tumour and benign lesions GSE41499: Expression profiling of ovarian cancer cell lines Refer to individual Series

2012-10-12 | E-GEOD-41500 | biostudies-arrayexpress

17β-estradiol accelerates ovarian tumour progression in vivo though the upregulation of GREB1

Project description:Exogenous 17β-estradiol (E2) accelerates the progression of ovarian cancer in the transgenic tgCAG-LS-TAg mouse model of the disease. We hypothesized that E2 has direct effects on ovarian cancer cells and this study was designed to determine the molecular mechanisms by which E2 accelerates ovarian tumour progression. Mouse ovarian cancer ascites (MASE2) cell lines were derived from tgCAG-LS-TAg mice. Following intraperitoneal engraftment of MASE2 into SCID mice, exogenous E2 significantly decreased the survival time and increased the tumour burden. Microarray analysis performed on cells derived from mouse ovarian cancer ascites (MASE2) treated with and without E2 indicated that E2 treatment caused the upregulation and downregulation of genes involved in cell differentiation, proliferation and migration. In particular, Greb1 that has been also identified as a hormone-responsive gene in breast cances, was upregulated in mouse tumour cells treated with E2.

2014-01-20 | GSE45271 | GEO

17β-estradiol accelerates ovarian tumour progression in vivo though the upregulation of GREB1

2014-01-20 | E-GEOD-45271 | biostudies-arrayexpress

Education of tumour-associated macrophages by the tumour matrisome inhibits immune surveillance

Project description:Metastatic ovarian tissues represent a complex tumour microenviroment. We analysed the tumour matrisome and immune cell environment in 39 metastatic ovarian tissues. We developed a disease score system, which positively correlated with the tumour matrisome. A distinct matrisome signature was identfied with increasing disease. Immune abundance and phenotype positively correaletd with tumour matrisome components. We developed a decellularised tissue model using metastatic ovarian omental tissues that maintained ECM protein content and architecture and cultured human blood-derived macrophages derived from four different donors. Monocytes cultured on high diseased tissues differerntiated into a distinct macrophage population, different from uninvovled (low disease) samples. Tumour ECM cultured macrophages had pro-tumorgenic phenotype and function.

2023-03-24 | GSE186145 | GEO

Investigation of the anti-tumour properties of interferon epsilon in high grade serous ovarian cancer

Project description:Investigation of the anti-tumour properties of interferon epsilon in high grade serous ovarian cancer

| PRJNA832125 | ENA

Transcription profiling of repeatedly thaw-frozen ovarian tumour samples

Project description:We evaluated the influence of repeatedly division of tumour samples at room temperature on gene expression profile. Experimental Design: four old (more than five years) ovarian tumour samples were divided twice on two different days giving a total of three aliquots each. RNA from the removed tissue aliquot was extracted and purified at the day of division and the remaining tissue re-frozen. The Trizol reagent kit and RNeasy MinElute kit were used for RNA extraction and purification. RNA quantity was evaluated on a spectrophotometer and quality was evaluated on the Agilent Bioanalyzer 2100. RNA from all three aliquots of the four old tumour samples were labeled with the ENZO kit and hybridized to twelve Affymetrix chips U133A 2.0. The four tumours were named 2, 3, 4 and 7. Aliquots from the first day are called "a", from the second day "b", the third day "c".

2005-10-01 | E-MEXP-398 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data